Ongoing Research

 
News Articles for Ongoing Research top ^
2014/12/15
PNM Resources’ (NYSE: PNM) management today announced the company’s 2015 ongoing earnings guidance range of $1.50 to $1.62 per diluted share.
Sign-up for PNM Resources Announces 2015 Ongoing Earnings Guidance Range investment picks
2015/1/29
RedHill and Quest Diagnostics concluded a pre-submission meeting with U.S. FDA regarding RedHill's companion diagnostic test for the detection of MAP bacterium, an extension of RedHill's ongoing RHB-104 Phase III Crohn's disease development program Increasing evidence supports the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients; Based of FDA's feedback, RedHill and Quest Diagnostics plan to commence a study to assess the clinical utility of the diagnostic test in Q2-Q3/2015 A protocol amendment for the ongoing Phase III study of RHB-104 in Crohn's disease has been filed with FDA and is expected to significantly increase the number of patients eligible to enroll in this study The RHB-104 Phase III MAP US study for Crohn's disease is one of RedHill's three ongoing Phase III studies in the U.S. with three of its drug candidates targeting gastrointestinal diseases TEL-AVIV, Israel, Jan.
Sign-up for RedHill Biopharma Provides Update on Progress With RHB-104 Ongoing Phase III Program for Crohn's Disease Following FDA Meeting investment picks
2014/12/7
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers SAN FRANCISCO, Dec.
Sign-up for Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies investment picks
2014/12/8
PNM Resources (NYSE: PNM) will announce the company's 2015 ongoing earnings guidance range prior to the market opening on Monday, Dec.
Sign-up for PNM Resources to Announce 2015 Ongoing Earnings Guidance Dec. 15 investment picks
2014/12/12
Company does not expect to make the cash interest payment due December 31 on convertible debentures VANCOUVER , Dec.
Sign-up for Ivanhoe Energy provides update on the status of ongoing strategic and financial initiatives to obtain additional financing investment picks
2015/1/7
Monsanto Company (NYSE: MON) delivered earnings per share for the first quarter of fiscal year 2015 ahead of expectations it outlined at the beginning of the fiscal year, with the company confirming full-year ongoing earnings per share growth and free cash flow guidance.
Sign-up for Monsanto First-Quarter Milestones Reinforce Foundation for Growth in FY15 and Confidence in Five-Year Plan to More Than Double Ongoing EPS investment picks
2015/2/10
The Securities Arbitration Law Firm of Klayman & Toskes (“K&T”), www.sueubspuertorico.com , and Carlo Law Offices, announced today that it has broadened its ongoing investigation of UBS Financial Services Inc. of Puerto Rico, as a result of the recording of former UBS Puerto Rico Chairman Miguel Ferrer pressuring brokers to sell risky Puerto Rico closed-end bond funds.
Sign-up for The Securities Arbitration Law Firm of Klayman & Toskes, PA and Carlo Law Offices Broadens Its Ongoing Investigation of UBS Financial Services of Puerto Rico Based on Newly Discovered Tape Recording of former UBS Puerto Rico Chairman Miguel Ferrer investment picks
2014/12/2
New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients New Data Show 43% Best Response Rate in 14 Renal-Evaluable Patients Cardiac and Renal Biomarker Responses of Single-Agent NEOD001-Treated Patients Compare Favorably with Historical Data in Patients with AL Amyloidosis NEOD001 Continues to be Safe and Well-Tolerated, with No Dose Limiting Toxicities Observed Excellent Pharmacokinetic Properties and No Immunogenicity Currently Enrolling Expansion Portion of Phase 1/2 Trial with New Data Expected to be Presented Annually at Appropriate Medical Conferences, Beginning in 2015 Prothena to Host Investor Conference Call and Webcast Today at 4:30 p.m. ET DUBLIN, Ireland, Dec.
Sign-up for Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis investment picks
2014/12/2
TEL-AVIV, Israel, Dec.
Sign-up for RedHill Biopharma to Sponsor and Exhibit Its Ongoing Phase III Crohn's Program at the Israeli IBD Society Meeting investment picks
2014/12/6
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163477&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting investment picks
2014/12/9
100% of evaluable CLL/SLL patients (9/9) had nodal reductions, with 6 of 9 patients achieving a PR with the remaining 3 patients on study with nodal reductions ranging from 15% to 45% and a peripheral response (normalization or >50% decrease in ALC) pending additional assessments 83% (5/6) of patients with Non-Hodgkin's Lymphoma; 3/3 DLBCL and 2/3 Follicular Lymphoma (FL) responded to the combination at the highest dose tested, including 2 CR's in patients with DLBCL confirmed by independent review Collectively, 87 patients have been treated with TGR-1202, alone or in combination with TG-1101, without the observance of drug-related hepatic toxicity Dose escalation continues with TGR-1202 at 800mg micronized The combination of TG-1101, TGR-1202, and ibrutinib ("Triple Therapy") was safely administered to 5 patients with heavily pre-treated NHL, CLL, and Richter's transformation with no dose limiting toxicities observed, and no Grade 3 or 4 events observed to
Sign-up for Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety investment picks
2014/12/8
BioLineRx Ltd.
Sign-up for BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference investment picks
2015/1/7
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin ® in diabetic nephropathy that has been accepted by the U.S. Food and Drug Administration under a Special Protocol Assessment.
Sign-up for NephroGenex Announces that the European Medicines Agency Supports the Company’s Study Design for Ongoing Trial in Diabetic Nephropathy investment picks
2015/1/5
Successful Dose Response Further Confirms Phase 3 Trial Design Company to Hold Conference Call at 8:30 a.m. ET on Monday, January 5, 2015 MENLO PARK, Calif.
Sign-up for Versartis Announces Positive 12 Month Data for VRS-317 from Ongoing Extension Study investment picks
2014/12/29
MENLO PARK, Calif., Dec.
Sign-up for Versartis to Hold Conference Call to Discuss VRS-317 Clinical Update From Ongoing Extension Study investment picks
2014/12/15
The collaboration, initiated two years ago, focuses on developing a customised harvester for the efficient, large-scale harvesting of castor beans in Latin America.
Sign-up for CNH Industrial and Evogene Subsidiary Announce Ongoing Collaboration for the Development of a Mechanised Harvesting Solution for Castor Beans investment picks
2014/12/22
TORONTO , Dec.
Sign-up for AuRico Gold Negotiates Receipt of C$20 Million Upfront Payment and Ongoing Royalty with Crocodile Gold investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Ongoing Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Ongoing Earnings Guidance  |  Next: Ongoing Research Collaboration